NO20052987D0 - Forbindelser for normalisering av sovn/vaken-syklusen. - Google Patents

Forbindelser for normalisering av sovn/vaken-syklusen.

Info

Publication number
NO20052987D0
NO20052987D0 NO20052987A NO20052987A NO20052987D0 NO 20052987 D0 NO20052987 D0 NO 20052987D0 NO 20052987 A NO20052987 A NO 20052987A NO 20052987 A NO20052987 A NO 20052987A NO 20052987 D0 NO20052987 D0 NO 20052987D0
Authority
NO
Norway
Prior art keywords
normalizing
sleep
compounds
wake cycle
wake
Prior art date
Application number
NO20052987A
Other languages
English (en)
Other versions
NO20052987L (no
Inventor
Scott Lukas
Perry F Renshaw
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of NO20052987D0 publication Critical patent/NO20052987D0/no
Publication of NO20052987L publication Critical patent/NO20052987L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052987A 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen. NO20052987L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (en) 2002-12-20 2003-12-17 Compounds for the normalization of the sleep/wake cycle

Publications (2)

Publication Number Publication Date
NO20052987D0 true NO20052987D0 (no) 2005-06-17
NO20052987L NO20052987L (no) 2005-08-29

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052987A NO20052987L (no) 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen.

Country Status (12)

Country Link
US (1) US20040176316A1 (no)
EP (1) EP1589979A4 (no)
JP (2) JP4717444B2 (no)
CN (1) CN100563660C (no)
AU (1) AU2003299715A1 (no)
BR (1) BR0317586A (no)
CA (1) CA2508995A1 (no)
MX (1) MXPA05006781A (no)
NO (1) NO20052987L (no)
RU (1) RU2366428C2 (no)
UA (1) UA88869C2 (no)
WO (1) WO2004058160A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
PT1565055E (pt) * 2002-11-08 2013-09-16 Mclean Hospital Corp Compostos para o tratamento da dependência e da privação de tabaco
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
JP2011502539A (ja) * 2007-11-16 2011-01-27 バイオ クリニカル デベロップメント，インコーポレイテッド 低カフェイン可食性活力組成物
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
JP6165852B2 (ja) * 2012-06-04 2017-07-19 ファイザー・インク 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用
KR102245628B1 (ko) * 2013-04-05 2021-04-28 라이온 가부시키가이샤 내복 조성물
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
JP3153551B2 (ja) * 1991-05-29 2001-04-09 アボツト・ラボラトリーズ 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
CA2213000A1 (en) * 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
WO1998006855A1 (en) * 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
DK1870103T3 (da) * 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
JP2011102319A (ja) 2011-05-26
JP2006513214A (ja) 2006-04-20
WO2004058160A3 (en) 2005-03-31
WO2004058160A2 (en) 2004-07-15
CN100563660C (zh) 2009-12-02
CA2508995A1 (en) 2004-07-15
JP4717444B2 (ja) 2011-07-06
AU2003299715A1 (en) 2004-07-22
UA88869C2 (ru) 2009-12-10
US20040176316A1 (en) 2004-09-09
EP1589979A2 (en) 2005-11-02
RU2005122934A (ru) 2006-01-20
AU2003299715A8 (en) 2004-07-22
BR0317586A (pt) 2005-11-22
EP1589979A4 (en) 2009-04-01
MXPA05006781A (es) 2005-09-30
NO20052987L (no) 2005-08-29
CN1750833A (zh) 2006-03-22
RU2366428C2 (ru) 2009-09-10

Similar Documents

Publication Publication Date Title
NO20053248D0 (no) Kerosenblanding.
AU2003299715A8 (en) Compounds for the normalization of the sleep/wake cycle
NO20052248D0 (no) Svivelstykkesystem.
DE60315471D1 (de) 2,5-disubstituierte 3-mercaptopentansaure
DE60324703D1 (de) Barbitursäure derivaten.
BRPI0308677A2 (pt) condensador.
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20032170A1 (it) Tagliacimosse.
ITMI20022179A1 (it) Il manopoliero
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ES1053179Y (es) Salvavidas perfeccionado.
ITRA20020023A1 (it) Il mollino.
ES1052590Y (es) Quiosco-consigna.
ITTO20020722A1 (it) Alchinilcarbossi-nucleotidi.
ES1051803Y (es) Andamio perfeccionado.
NL1024812A1 (nl) Lampenkap.
ES1052052Y (es) Brida.
ES1051950Y (es) Celosia fija.
ES1050939Y (es) Celosia antivandalica.
ES1053801Y (es) Salvavidas perfeccionado.
FI20020644A0 (fi) Kompleksiliuos
MA25629A1 (fr) Reacteur : aero-hydro-electrique.
ES1051316Y (es) Quiosco.
ES1051515Y (es) Estuche perfeccionado.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application